Next Article in Journal
Influence of Socioeconomic Status on Knowledge of Obesity and Diabetes among Adolescents in Chennai, South India
Next Article in Special Issue
Persistent Pulmonary Hypertension in the Newborn
Previous Article in Journal
One Size Does Not Fit All: Contextualising Family Physical Activity Using a Write, Draw, Show and Tell Approach
Article Menu

Export Article

Open AccessReview
Children 2017, 4(7), 60;

Sildenafil in Infants and Children

Department of Congenital Heart Disease, Bristol Royal Hospital for Children, Bristol BS2 8BJ, UK
Author to whom correspondence should be addressed.
Academic Editor: Maria Serratto
Received: 17 May 2017 / Revised: 8 July 2017 / Accepted: 21 July 2017 / Published: 24 July 2017
(This article belongs to the Special Issue New Trend in Pediatric Cardiology: Pulmonary Hypertension)
Full-Text   |   PDF [231 KB, uploaded 24 July 2017]


Pulmonary arterial hypertension (PAH) management has been transformed in recent times with the advent of cheap and effective diagnostic tools and therapy. Sildenafil, a phosphodiesterase-V inhibitor, has been at the centre of this treatment, and its success in treating PAH has led to its widespread uptake in adult and paediatric pulmonary hypertension (PH), as a first line treatment choice. This might apply to persistent pulmonary hypertension of the newborn (PPHN) or bronchopulmonary dysplasia, as well as to more complex diseases, such as idiopathic pulmonary hypertension. Although recent data regarding long-term mortality and the repeal of Food and Drug Administration (FDA) approval has complicated the issue, Sildenafil continues to be the major treatment option for paediatric PH for patients in a variety of contexts, and this does not seem likely to change in the foreseeable future. In this review, we provide a summary of pulmonary hypertension in infants and children and the use of Sildenafil for such diseases. View Full-Text
Keywords: pulmonary hypertension; Sildenafil; phosphodiesterase inhibitor pulmonary hypertension; Sildenafil; phosphodiesterase inhibitor
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Simonca, L.; Tulloh, R. Sildenafil in Infants and Children. Children 2017, 4, 60.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Children EISSN 2227-9067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top